Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
announced that Ryan Daws, Chief Financial Officer, will be
leaving the company in early June 2017 to return to investment
banking. He will be joining Baird as Managing Director in the
firm’s Life Sciences and Biotechnology Group. Mr. Daws will
continue to consult with the Company, including through the
closing of the pending asset purchase agreement with Vertex
Pharmaceuticals, Inc. Mr. Daws served as CFO of Concert since
January 2014. Concert has initiated a search to appoint a new
CFO.
|
(d)
|
Exhibits
|
Exhibit Index attached hereto.
About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Recent Trading Information
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) closed its last trading session 00.00 at 13.18 with 250,302 shares trading hands.
